NIPH Stock Overview
The Nile Co. for Pharmaceuticals and Chemical Industries develops, produces, and sells pharmaceutical products primarily in the Middle East.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 3/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
+ 1 more risk
The Nile Co. for Pharmaceuticals and Chemical Industries Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ج.م43.00 |
52 Week High | ج.م48.99 |
52 Week Low | ج.م28.44 |
Beta | 0.16 |
1 Month Change | -7.90% |
3 Month Change | 7.53% |
1 Year Change | 21.09% |
3 Year Change | 32.47% |
5 Year Change | 320.74% |
Change since IPO | 187.95% |
Recent News & Updates
Recent updates
Shareholder Returns
NIPH | EG Pharmaceuticals | EG Market | |
---|---|---|---|
7D | -2.6% | -0.6% | 3.2% |
1Y | 21.1% | 13.8% | 77.1% |
Return vs Industry: NIPH exceeded the EG Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: NIPH underperformed the EG Market which returned 75% over the past year.
Price Volatility
NIPH volatility | |
---|---|
NIPH Average Weekly Movement | 5.3% |
Pharmaceuticals Industry Average Movement | 3.7% |
Market Average Movement | 4.5% |
10% most volatile stocks in EG Market | 7.6% |
10% least volatile stocks in EG Market | 2.6% |
Stable Share Price: NIPH is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: NIPH's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1962 | n/a | Khaled Salah Hagag | https://www.nilepharma.com.eg |
The Nile Co. for Pharmaceuticals and Chemical Industries develops, produces, and sells pharmaceutical products primarily in the Middle East. The company offers prescription pharmaceutical products, including tablets, capsules, dry syrups, syrups and suspensions, ointments, gels and creams, suppositories, ampoules, drops, parenteral, sachets, biotechnological products, lyophilized products, sterile antibiotic vials, lotions, shampoos, and solutions. It also provides non-prescription pharmaceutical products, such as analgesic and anti-inflammatory, antihistaminic, anthelmintic, antibacterial, antifungal, cardiovascular disorders, central nervous system and antiparkinsonism drugs, oral cavity products, respiratory system disorders, urinary tract disorders, endocrine glands disorders, gastrointestinal tract disorders, muscle relaxants, topical otic and nasal preparations, topical ophthalmological preparations, dermatological preparations, women and men healthcare products, osteoporosis, pediatrics, cosmetics, antiseptics, and immunological products, as well as vitamins and minerals.
The Nile Co. for Pharmaceuticals and Chemical Industries Fundamentals Summary
NIPH fundamental statistics | |
---|---|
Market Cap | ج.م435.38m |
Earnings (TTM) | ج.م94.03m |
Revenue (TTM) | ج.م936.31m |
4.6x
P/E Ratio0.5x
P/S RatioIs NIPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NIPH income statement (TTM) | |
---|---|
Revenue | ج.م936.31m |
Cost of Revenue | ج.م699.81m |
Gross Profit | ج.م236.50m |
Other Expenses | ج.م142.47m |
Earnings | ج.م94.03m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 9.29 |
Gross Margin | 25.26% |
Net Profit Margin | 10.04% |
Debt/Equity Ratio | 70.1% |
How did NIPH perform over the long term?
See historical performance and comparison